Form 4: Helius Medical Technologies CEO Dane Andreeff Receives Stock Option Grant
SEC Form 4
Dane Andreeff, CEO of Helius Medical Technologies, was granted a stock option to purchase 279,715 shares of Class A Common Stock on January 6, 2025.
Summary
- On January 6, 2025, Dane Andreeff, the President and CEO of Helius Medical Technologies, received a stock option grant for 279,715 shares of Class A Common Stock.
- The exercise price of the option is $0.7292 per share.
- 50% of the options vested immediately, and the remaining options will vest in twelve equal quarterly installments starting March 31, 2025, contingent upon continued service.
- The options expire on January 5, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive event.
Positives
- The stock option grant aligns the CEO's interests with those of the shareholders.
- The vesting schedule incentivizes continued service and performance.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- The size of the grant and vesting schedule are typical for companies of Helius Medical Technologies' size and stage of development.
- Comparable companies such as Neuronetics, Inc. and Biohaven Pharmaceutical Holding Company also utilize stock options as part of their executive compensation strategy.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CEO to drive company growth.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 01/06/2025 | Date of stock option grant |
| 03/31/2025 | Start date for quarterly vesting installments |
| 01/05/2035 | Expiration date of the stock option |
| 01/08/2025 | Date of signature |
Keywords
stock option, Helius Medical Technologies, CEO, Dane Andreeff, equity incentive, vesting, HSDT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.